We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Innovative Blood Test Aids Early Detection of Breast Cancer

By LabMedica International staff writers
Posted on 25 Nov 2019
Print article
Image: A simple blood test could diagnose breast cancer up to five years before symptoms occur. The presence of autoantibodies, that compliment tumor-associated antigens, help to diagnose breast cancer earlier (Photo courtesy of Oncology Central).
Image: A simple blood test could diagnose breast cancer up to five years before symptoms occur. The presence of autoantibodies, that compliment tumor-associated antigens, help to diagnose breast cancer earlier (Photo courtesy of Oncology Central).
A blood test is being developed that could help detect breast cancer five years before any symptoms become apparent. This method would also be less uncomfortable and more cost effective than traditional mammograms.

Early diagnosis of cancer is paramount to improved survival by enabling treatment prior to cancer spreading, when tumors should be both surgically removable and curable. Autoantibodies against numbers of tumor-associated antigens (TAAs) have been shown to be relevant tumor biomarkers and can be detected up to five years before the tumor is overt clinically.

A team of scientists working at the University of Nottingham (Nottingham, UK) first developed panels of tumor-associated antigens (TAAs) specific to breast cancer. This allowed them to screen for the presence of autoantigens in blood that are associated with a response to breast cancer-specific TAAs. In a pilot study, they screened 180 breast cancer matched control samples for the presence of autoantibodies against 67 TAAs which have already been shown to involve in breast cancer pathology. Optimized Protein microarray technology was applied for this study. They used specialized screening methods to look for autoantibodies generated against 40 TAAs they already knew were associated with blood cancer and 27 TAAs that were not known to have a link with this type of cancer.

In total, the team developed three panels of TAAs that allowed them to screen for autoantibodies that respond to them, and, the investigators noted, the more TAAs present in a panel, the more accurate the blood test results. The panel featuring five TAAs facilitated the correct detection of breast cancer in 29% of the samples from people with breast cancer. It also confirmed the lack of breast cancer in 84% of the samples from the control group. The panel featuring seven TAAs allowed for the correct detection of breast cancer in 35% of the samples collected from people with cancer, and it confirmed the lack of cancer in 79% of the samples from people without cancer. The panel containing nine TAAs led to the detection of cancer in 37% of the samples from individuals with breast cancer, and it confirmed the lack of cancer in 79% of the control samples.

Daniyah Alfattani, a PhD student and co-author of the study, said, “The results of our study showed that breast cancer does induce autoantibodies against panels of specific TAAs. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood. This innovative blood test could help specialists detect the presence of breast cancer up to five years before any visible symptoms occur.” The study was presented at the 2019 National Cancer Research Institute conference held November 3-5, 2019 in Glasgow, UK.

Related Links:
University of Nottingham

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.